纯导管原位癌诊断后乳腺癌死亡与浸润性复发的危险因素不同
该研究基于SEER数据库纳入29,515例纯导管原位癌女性患者,采用竞争风险模型分别分析乳腺内浸润性复发与乳腺癌死亡的独立危险因素。结果显示两者危险因素并不一致:乳腺内浸润性复发并非导管原位癌患者乳腺癌特异性死亡的唯一决定因素。
要点
- 导管原位癌诊断后乳腺内浸润性复发与乳腺癌死亡的危险因素并不相同。
- 年龄、Black种族、弥漫性病变与乳腺癌死亡相关,保乳加放疗和全乳切除与死亡风险降低相关。
- 临床随访不宜仅以乳腺内浸润性复发作为导管原位癌患者死亡风险的替代指标。
核心结论
- 纯导管原位癌诊断后,乳腺内浸润性复发的危险因素与乳腺癌死亡的危险因素不同,乳腺内浸润性复发并非乳腺癌特异性死亡的唯一考量。
研究设计与样本
- 回顾性队列研究,查询监测、流行病学和最终结果(SEER)项目,纳入诊断为纯导管原位癌的女性患者共29,515例。
- 采用竞争风险模型估计累积发生率,并以竞争风险回归分别分析乳腺内浸润性复发与乳腺癌死亡。
- 乳腺内浸润性复发分析以乳腺和非乳腺癌死亡为竞争风险,乳腺癌死亡分析以非乳腺癌死亡为竞争风险。
主要发现
- 29,515例患者中,164例未经历 intervening 浸润性复发即发生乳腺癌死亡,44例在乳腺内浸润性复发后发生乳腺癌死亡。
- 乳腺内浸润性复发的显著因素包括病变>5 cm(HR=1.59,95%CI 1.24-2.04,P<.001)、弥漫性病变(HR=0.0005,95%CI 0.0003-0.0007,P<.001)、其他种族(HR=1.29,95%CI 1.10-1.52,P=.002)、Black种族(HR=1.21,95%CI 1.01-1.46,P=.04)、诊断年龄(HR=0.99,95%CI 0.98-1.00,P=.02)、低级别病变(HR=0.79,95%CI 0.64-0.96,P=.02)、保乳加放疗(HR=0.67,95%CI 0.58-0.77,P<.001)和全乳切除(HR=0.36,95%CI 0.30-0.44,P<.001)。
- 乳腺癌死亡的显著因素包括诊断年龄(HR=1.04,95%CI 1.03-1.05,P<.001)、Black种族(HR=2.88,95%CI 2.08-3.99,P<.001)、弥漫性病变(HR=6.02,95%CI 1.39-26.07,P=.02)、保乳加放疗(HR=0.51,95%CI 0.36-0.72,P<.001)和全乳切除(HR=0.60,95%CI 0.50-0.92,P=.02)。
临床怎么用
- 对纯导管原位癌患者评估预后时,应分别看待浸润性复发风险与乳腺癌死亡风险,不能以复发风险直接替代死亡风险。
- 具有年龄、Black种族、弥漫性病变等死亡相关因素的患者可能需要更密切的长期随访。
- 治疗决策中保乳加放疗和全乳切除与两项结局风险降低相关,但需结合患者个体因素综合判断。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer mortality after ductal carcinoma in situ is rare, making it difficult to predict which patients are at risk and to identify whether risk factors for this outcome are the same as those for invasive recurrence. We aimed to identify whether risk factors for invasive recurrences are similar to those for breast cancer death after a diagnosis of pure ductal carcinoma in situ. METHODS: The Surveillance, Epidemiology, and End Results Program was queried for female patients diagnosed with pure ductal carcinoma in situ. Cumulative incidence was estimated by treatment group using competing risks. Competing risks regression was then performed for the development of in-breast invasive recurrence with competing risks of breast and non-breast cancer death. Competing risks regression was then again performed for development of breast cancer mortality with the competing risk of non-breast cancer death. RESULTS: A total of 29,515 patients were identified. Of them, 164 patients suffered breast cancer mortality without an intervening invasive recurrence, and 44 suffered breast cancer mortality after an invasive in-breast recurrence. On competing risks analysis for invasive in-breast recurrence, significant factors included lesion size >5 cm (hazard ratio = 1.59, 95% confidence interval 1.24-2.04, P < .001), diffuse disease (hazard ratio = 0.0005, 95% confidence interval 0.0003-0.0007, P < .001), other race (hazard ratio = 1.29, 95% confidence interval 1.10-1.52, P = .002), Black race (hazard ratio = 1.21, 95% confidence interval 1.01-1.46, P = .04), age at diagnosis (hazard ratio = 0.99, confidence interval 0.98-1.00, P = .02), low-grade disease (hazard ratio = 0.79, 95% confidence interval 0.64-0.96, P = .02), lumpectomy with radiation (hazard ratio = 0.67, 95% confidence interval 0.58-0.77, P < .001), and mastectomy (hazard ratio = 0.36, 95% confidence interval 0.30-0.44, P < .001). Significant factors for breast cancer mortality included age at diagnosis (hazard ratio = 1.04, 95% confidence interval 1.03-1.05, P < .001), Black race (hazard ratio = 2.88, 95% confidence interval 2.08-3.99, P < .001), diffuse disease (hazard ratio = 6.02, 95% confidence interval 1.39-26.07, P = .02), lumpectomy with radiation (hazard ratio = 0.51, 95% confidence interval 0.36-0.72, P < .001), and mastectomy (hazard ratio = 0.60, 95% confidence interval 0.50-0.92, P = .02). CONCLUSION: Our results suggested that risk factors for in-breast invasive recurrence after a diagnosis of pure ductal carcinoma in situ differ from risk factors for breast cancer mortality and development of metastatic recurrence. In-breast invasive recurrence is not the only consideration for breast cancer specific mortality in ductal carcinoma in situ patients.
引用
- O'Keefe TJ, Chau H, Harismendy O, et al. Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence. Surgery. 2022. PMID: 36435650. doi:10.1016/j.surg.2022.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。